ONCO-INNOVATIONS LTD ONNVF overview

VANCOUVER, BC / ACCESS Newswire / April 10, 2025 / Onco-Innovations Limited (CSE: ONCO )(OTCQB: ONNVF )(Frankfurt: W1H , WKN: A3EKSZ ) (" Onco " or the " Company ") is pleased to announce that its subsidiary, Inka Health Corp. (" Inka Health "), has published a significant and novel study titled Quantitative Bias Analysis for the Assessment of Bias in Comparisons between Synthetic Control Arms (the " Study ") published in JAMA Network Open[1] in March 2025, addressing a critical methodological...

VANCOUVER, BC / ACCESS Newswire / April 3, 2025 / Onco-Innovations Limited (CSE: ONCO )(OTCQB: ONNVF )(Frankfurt: W1H , WKN: A3EKSZ ) (" Onco " or the " Company ") is pleased to announce that its wholly owned subsidiary, Inka Health Corp. (" Inka Health "), which the Company acquired on or about February 3, 2025 (please see news release dated February 3, 2025), has now successfully completed analytical work under contract (" AZ Services Agreement ") for AstraZeneca Canada (" AstraZeneca "),...

VANCOUVER, BC / ACCESS Newswire / March 26, 2025 / Onco-Innovations Limited (CSE: ONCO )(OTCQB: ONNVF )(Frankfurt: W1H , WKN: A3EKSZ ) (" Onco " or the " Company ") is pleased to provide information regarding its second-generation nanoparticle formulation of Polynucleotide Kinase 3'-Phosphatase (PNKP) Compound (the " Technology ") in combination with radiation therapy, which has demonstrated, in a December 2021 study[1] conducted by researchers at the University of Alberta, Canada, effective...

VANCOUVER, BC / ACCESS Newswire / March 25, 2025 / Onco-Innovations Limited (CSE: ONCO )(OTCQB: ONNVF )(Frankfurt: W1H , WKN: A3EKSZ ) (" Onco " or the " Company ") announces that it has extended the term of its engagement with MCS Market Communication Service GmbH (business address: Rheinpromenade 13, 40789 Monheim am Rhein, Nordrhein-Westfalen, Deutschland, email: [email protected]; telephone: +491772481220; and website: www.mcsmarket.de) ("MCS") for the continued provision of a range of...

VANCOUVER, BC / ACCESS Newswire / March 24, 2025 / Onco-Innovations Limited (CSE: ONCO )(OTCQB: ONNVF )(Frankfurt: W1H ), (WKN: A3EKSZ ) (" Onco " or the " Company "), at the request of the Canadian Securities Exchange, provides, by way of the table below, an update to the use of proceeds disclosure contained in its prospectus dated November 25, 2024 (" Prospectus "). Principal Purposes as described in Prospectus Maximum Offering(i) ($) Use of Funds to Date(ii) Projected remaining cost to...

VANCOUVER, BC / ACCESS Newswire / March 2, 2025 / Onco-Innovations Limited (CSE: ONCO )(OTCQB: ONNVF )(Frankfurt: W1H )(WKN: A3EKSZ ) (" Onco " or the " Company ") is pleased to announce that its CEO, Thomas O'Shaughnessy, was recently featured in an exclusive interview on Conversations That Matter , a widely distributed long-form program showcasing thought leaders shaping the world. The program is featured in the Vancouver Sun and is broadcast across multiple television networks in British...

VANCOUVER, BC / ACCESS Newswire / February 27, 2025 / Onco-Innovations Limited (CSE: ONCO )(OTCQB: ONNVF )(Frankfurt: W1H ,WKN: A3EKSZ ) (" Onco " or the " Company ") is pleased to provide information regarding its wholly-owned subsidiary, Inka Health ("Inka"), which has made significant strides in advancing AI-driven oncology research by leading a transformative study protocol 1 published in medRxiv in September 2024 , focused on AI-generated synthetic patient models. This innovative research...

VANCOUVER, BC / ACCESS Newswire / February 24, 2025 / Onco-Innovations Limited(CSE: ONCO )(OTCQB: ONNVF )(Frankfurt: W1H ,WKN: A3EKSZ ) (" Onco " or the " Company ") is pleased to provide information regarding its second-generation nanoparticle formulation of Polynucleotide Kinase 3'-Phosphatase (PNKP) Compound (the " Technology "), specifically that it has demonstrated enhanced PNKP inhibitor delivery, enabling solubilization with minimal toxicity, in a June 2021 study [1] conducted by...